BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › A Prognostic Gene Expression Index in Ovarian Cancer

Dataset: A Prognostic Gene Expression Index in Ovarian Cancer

Ovarian carcinoma has the highest mortality rate among gynecological malignancies. In this project, we investigated the hypothesis that...

Registered by ArrayExpress Uploader
View Dataset

Ovarian carcinoma has the highest mortality rate among gynecological malignancies. In this project, we investigated the hypothesis that molecular markers are able to predict outcome of ovarian cancer independently of classical clinical predictors, and that these molecular markers can be validated using independent data sets. We applied a semi-supervised method for prediction of patient survival. Microarrays from a cohort of 80 ovarian carcinomas (TOC cohort) were used for the development of a predictive model, which was then evaluated in an entirely independent cohort of 118 carcinomas (Duke cohort). A 300 gene ovarian prognostic index (OPI) was generated and validated in a leave-one-out approach in the TOC cohort (Kaplan-Meier analysis, p=0.0087). In a second validation step the prognostic power of the OPI was confirmed in an independent data set (Duke cohort, p=0.0063). In multivariate analysis, the OPI was independent of the postoperative residual tumour, the main clinico-pathological prognostic parameter with an adjusted hazard ratio of 6.4 (TOC cohort, CI 1.8 – 23.5, p=0.0049) and 1.9 (Duke cohort, CI 1.2 – 3.0, p=0.0068). We constructed a combined score of molecular data (OPI) and clinical parameters (residual tumour), which was able to define patient groups with highly significant differences in survival. The integrated analysis of gene expression data as well as residual tumour can be used for optimised assessment of prognosis. As traditional treatment options are limited, this analysis may be able to optimise clinical management and to identify those patients that would be candidates for new therapeutic strategies. Keywords: disease state analysis RNA from 80 frozen ovarian cancer samples was analysed with oligonucleotide microarrays

Species:
human

Samples:
80

Source:
E-GEOD-14764

PubMed:
19294737

Updated:
Jan.17, 2015

Registered:
Jan.17, 2015


Factors: (via ArrayExpress)
Sample RESIDUAL TUMOR GRADE OVERALL SURVIVAL TIME FIGO STAGE OVERALL SURVIVAL EVENT HISTOLOGICAL TYPE
GSM368661 1 0.0 III 39 4 0 serous ovca
GSM368662 1 1.0 III 35 3c 0 serous ovca
GSM368663 1 1.0 III 27 3b 0 transitional cell ca
GSM368664 1 0.0 III 14 3c 0 serous ovca
GSM368665 1 1.0 III 46 3c 0 serous ovca
GSM368666 1 0.0 II 37 3c 0 serous ovca
GSM368667 1 0.0 III 36 1a 0 serous ovca
GSM368668 1 0.0 III 12 3c 0 serous ovca
GSM368669 1 0.0 I 70 1a 0 endometr ovca
GSM368670 1 0.0 III 35 3c 0 serous ovca
GSM368671 1 1.0 III 54 3c 0 serous ovca
GSM368672 1 0.0 III 68 3c 0 endometr ovca
GSM368673 1 0.0 III 40 3c 0 serous ovca
GSM368674 1 0.0 II 18 3c 1 serous ovca
GSM368675 1 nan III 30 3c 1 serous ovca
GSM368676 1 0.0 II 45 1a 0 clear cell ovca
GSM368677 1 0.0 III 40 2b 0 serous ovca
GSM368678 1 0.0 III 67 3c 0 serous ovca
GSM368679 1 1.0 III 31 3c 1 serous ovca
GSM368680 1 0.0 II 38 3c 0 serous ovca
GSM368681 1 0.0 III 43 3c 0 serous ovca
GSM368682 1 0.0 III 29 1c 0 serous ovca
GSM368683 1 1.0 III 12 3c 1 serous ovca
GSM368684 1 0.0 III 51 1c 1 clear cell ovca
GSM368685 1 1.0 III 40 3c 0 serous ovca
GSM368686 1 0.0 III 37 1a 0 endometr, clear cell ovca
GSM368687 1 0.0 III 49 1b 0 endometr ovca
GSM368688 1 0.0 III 36 1c 0 endometr ovca
GSM368689 1 nan III 49 3c 0 serous ovca
GSM368690 1 nan II 46 3c 1 serous ovca
GSM368691 1 1.0 III 20 3c 0 serous ovca
GSM368692 1 0.0 III 37 3c 0 serous ovca
GSM368693 1 0.0 II 37 3b 0 serous ovca
GSM368694 1 0.0 III 40 3b 1 serous ovca
GSM368695 1 1.0 III 47 3c 0 serous ovca
GSM368696 1 1.0 II 42 3b 0 serous ovca
GSM368697 1 0.0 II 52 3c 0 serous ovca
GSM368698 1 nan III 22 3c 0 serous ovca
GSM368699 1 0.0 III 45 3c 1 serous ovca
GSM368700 1 1.0 III 20 3c 1 serous ovca
GSM368701 1 0.0 II 45 3c 0 serous ovca
GSM368702 1 0.0 III 32 4 0 endometr ovca
GSM368703 1 0.0 III 49 3c 0 serous ovca
GSM368704 1 1.0 II 15 3c 0 serous ovca
GSM368705 1 1.0 II 43 3 1 serous ovca
GSM368706 1 0.0 I 73 3 0 serous ovca
GSM368707 1 0.0 III 53 3 1 serous ovca
GSM368708 1 1.0 I 38 3 1 serous ovca
GSM368709 1 0.0 III 51 3 0 serous ovca
GSM368710 1 1.0 III 55 3 1 serous ovca
GSM368711 1 0.0 II 27 3 1 serous ovca
GSM368712 1 1.0 III 7 3 1 endometr ovca
GSM368713 1 0.0 II 44 3 0 serous ovca
GSM368714 1 0.0 III 22 3 0 serous ovca
GSM368715 1 1.0 III 36 3 0 serous ovca
GSM368716 1 0.0 II 35 3 0 serous ovca
GSM368717 1 0.0 II 34 3 0 serous ovca
GSM368718 1 1.0 III 34 3 0 sarcomatoid
GSM368719 1 0.0 II 23 3 0 serous ovca
GSM368720 1 0.0 III 24 3 0 serous ovca
GSM368721 1 0.0 III 25 3 0 serous ovca
GSM368722 1 0.0 III 25 3 0 serous ovca
GSM368723 1 0.0 III 21 3 0 serous ovca
GSM368724 1 1.0 III 12 3 1 serous ovca
GSM368725 1 0.0 III 13 3 1 serous ovca
GSM368726 1 0.0 III 7 3 0 serous ovca
GSM368727 1 0.0 II 10 3 0 serous ovca
GSM368728 1 1.0 III 20 3 1 serous ovca
GSM368729 1 0.0 II 58 3 0 serous ovca
GSM368730 1 1.0 II 13 3 1 serous ovca
GSM368731 1 1.0 III 8 3 1 serous ovca
GSM368732 1 0.0 III 15 3 1 serous ovca
GSM368733 1 1.0 III 27 3 0 undifferentiated ovca
GSM368734 1 0.0 III 23 3 0 serous ovca
GSM368735 1 0.0 II 29 3 0 serous ovca
GSM368736 1 0.0 III 25 3 0 serous ovca
GSM368737 1 1.0 III 20 3 0 serous ovca
GSM368738 1 1.0 II 23 3 0 serous ovca
GSM368739 1 0.0 II 24 3 0 serous ovca
GSM368740 1 1.0 II 21 3 0 serous ovca

Tags

  • cancer
  • carcinoma
  • disease
  • ovarian cancer
  • ovarian carcinoma

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use